Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria

Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria

Chronic urticaria (CU) is a debilitating skin disease affecting around 1% of the population. CU can be subdivided into chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Different pathophysiological mechanisms have been proposed to play a role in the development of CU, and...

Full description

Bibliographic Details
Main Authors: Nadja Højgaard Pedersen, Jennifer Astrup Sørensen, Misbah Noshela Ghazanfar, Ditte Georgina Zhang, Christian Vestergaard, Simon Francis Thomsen
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:International Journal of Molecular Sciences
Subjects:
chronic urticaria
chronic spontaneous urticaria
biomarkers
omalizumab
anti-IgE
treatment response
Online Access:https://www.mdpi.com/1422-0067/24/14/11328

Internet

https://www.mdpi.com/1422-0067/24/14/11328

Similar Items